How the product works:
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite. The 2.5 mg dose is used as an initiation dose to improve tolerability.
Who it is recommended for:
Clinical studies and evidence:
Tirzepatide has been evaluated in the global SURPASS clinical trial program. Studies demonstrated significant reductions in HbA1c and improved glycemic outcomes. The 2.5 mg dose is widely used to initiate therapy safely before dose escalation.
Indicated for the treatment of type 2 diabetes mellitus to improve glycemic control. Used as an initial dose to support metabolic adaptation and prepare patients for further dose increases.
Administered as a subcutaneous injection once weekly in the abdomen, thigh, or upper arm. One prefilled pen provides four doses, covering one full month of therapy. Treatment regimen should be determined by a healthcare professional.
Contraindications
Side effects
